Skip to main content

Heat Biologics, Inc. (HTBX)

NASDAQ: HTBX · IEX Real-Time Price · USD
6.15
+0.03 (0.49%)
After-hours:Sep 24, 2021 7:22 PM EDT
6.12
-0.15 (-2.39%)
At close: Sep 24, 4:00 PM
Market Cap155.43M
Revenue (ttm)2.45M
Net Income (ttm)-29.38M
Shares Out25.14M
EPS (ttm)-1.27
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume164,721
Open6.20
Previous Close6.27
Day's Range6.10 - 6.29
52-Week Range5.22 - 17.00
Beta0.43
AnalystsStrong Buy
Price Target20.67 (+237.7%)
Est. Earnings DateNov 9, 2021

About HTBX

Heat Biologics, Inc., a biopharmaceutical company, engages in the development of immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which is in phase II clinical trials to treat patients with a...

IndustryBiotechnology
IPO DateJul 24, 2013
CEOJeffrey Wolf
Employees39
Stock ExchangeNASDAQ
Ticker SymbolHTBX
Full Company Profile

Financial Performance

In 2020, Heat Biologics's revenue was $2.95 million, a decrease of -3.32% compared to the previous year's $3.05 million. Losses were -$26.05 million, 30.1% more than in 2019.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for Heat Biologics stock is "Strong Buy." The 12-month stock price forecast is 20.67, which is an increase of 237.75% from the latest price.

Price Target
$20.67
(237.75% upside)
Analyst Consensus: Strong Buy

News

Heat Biologics CEO to Present at the Cantor Fitzgerald Global Healthcare Conference on September 29th

DURHAM, N.C., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune sys...

1 week ago - GlobeNewsWire

Heat Biologics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

DURHAM, N.C., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune sys...

2 weeks ago - GlobeNewsWire

Heat Biologics to Provide Corporate Update

Conference call scheduled for September 2nd at 11:00 AM ET Conference call scheduled for September 2nd at 11:00 AM ET

3 weeks ago - GlobeNewsWire

Heat Biologics Is Starting To Run Away From Support Toward Resistance

Heat Biologics Inc. (NASDAQ:HTBX) shares traded higher Thursday morning after the company announced the launch of its wholly-owned subsidiary Skunkworx Bio Inc. focused on developing a drug discovery pa...

4 weeks ago - Benzinga

Heat Biologics Unveils Skunkworx Bio, New Drug Discovery Subsidiary

Developing a new era of precision medicines using a unique and proprietary drug discovery platform Developing a new era of precision medicines using a unique and proprietary drug discovery platform

4 weeks ago - GlobeNewsWire

Heat Biologics Announces Addition of Former US Senator Mark Pryor to Biothreat Advisory Board

DURHAM, N.C., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the im...

1 month ago - GlobeNewsWire

Heat Biologics Provides Second Quarter 2021 Business Update

DURHAM, N.C., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the im...

1 month ago - GlobeNewsWire

Heat Biologics Announces Groundbreaking for New San Antonio Facility

Groundbreaking ceremony to be streamed live Groundbreaking ceremony to be streamed live

1 month ago - GlobeNewsWire

Heat Biologics Joins Russell Microcap® Index

DURHAM, N.C., June 28, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune syst...

2 months ago - GlobeNewsWire

Heat Biologics Announces Significant Expansion of R&D and Pre-Clinical Capabilities at Corporate Headquarters

Investments expected to accelerate development timelines and reduce development expenses Investments expected to accelerate development timelines and reduce development expenses

3 months ago - GlobeNewsWire

Heat Biologics Surges On Patent Filing

Heat Biologics Inc. (NASDAQ:HTBX) shares traded higher Thursday after the company filed for a patent titled “GP96-Based Cancer Therapy.” The stock was trending on StockTwits throughout the day and is li...

3 months ago - Benzinga

Heat Biologics to Showcase Favorable Survival Data of HS-110 in Previously Treated Non-Small Cell Lung Cancer Patient...

Survival benefit observed in two treatment settings of previously treated non-small lung cancer patients Survival benefit observed in two treatment settings of previously treated non-small lung cancer p...

3 months ago - GlobeNewsWire

Heat Biologics' Lead Candidate Shows Overall Survival Benefit In Lung Cancer Study

Heat Biologics Inc (NASDAQ: HTBX) has reported interim data from the Phase 1/2 trial evaluating its lead product, HS-110, in combination with Bristol-Myers Squibb Co's (NYSE: BMY) Opdivo (nivolumab) in ...

4 months ago - Benzinga

Heat Biologics Announces Promising Survival Data of HS-110 in Two Treatment Settings of Lung Cancer; Selected for Pre...

DURHAM, N.C., May 20, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune syste...

4 months ago - GlobeNewsWire

Heat Biologics Announces Multiple Presentations on PTX-35 at the Upcoming 3rd Annual Treg Directed Therapies Summit

DURHAM, N.C., May 19, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune syste...

4 months ago - GlobeNewsWire

Heat Biologics Appoints Anthony Manning, Ph.D. as Chief Scientific Advisor

DURHAM, N.C., May 10, 2021 (GLOBE NEWSWIRE) --  Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune syst...

4 months ago - GlobeNewsWire

Heat Biologics Provides First Quarter 2021 Business Update; Reports Continued Progress on Oncology and COVID-19 Vacci...

DURHAM, N.C., May 05, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the imm...

4 months ago - GlobeNewsWire

NSPR Stock: What You Should Know About InspireMD Today

InspireMD has vastly reduced the number of its shares trading ahead of a likely move to a Nasdaq listed. Conversion of NSPR stock warrants and preferred shares will be more difficult now.

Other symbols:NSPR
4 months ago - InvestorPlace

Heat Biologics Announces New Preclinical Data on PTX-35, Demonstrating Decreased Regulatory T-cell (Treg) Activity an...

DURHAM, NC / ACCESSWIRE / April 12, 2021 / Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, in...

5 months ago - Accesswire

Heat Biologics Provides Year-End Business Update

DURHAM, NC / ACCESSWIRE / March 25, 2021 / Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, in...

6 months ago - Accesswire

Heat Biologics to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference

DURHAM, NC / ACCESSWIRE / March 8, 2021 / Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, inc...

6 months ago - Accesswire

HTBX Stock: Why Shares of Heat Biologics Are Blazing Higher Today

Heat Biologics (HTBX) stock is heating up on Wednesday following new coverage from Cantor Fitzgerald analyst Kristen Kluska. The post HTBX Stock: Why Shares of Heat Biologics Are Blazing Higher Today ap...

6 months ago - InvestorPlace

Heat Biologics Catapults After Drug Regimen Boosts Lung-Cancer Survival

Heat Biologics said Tuesday adding its experimental drug to Bristol Myers Squibb's Opdivo helped more lung-cancer patients survive. In response, HTBX stock catapulted.

7 months ago - Investors Business Daily

Heat Biologics News: Why HTBX Stock Is Going Gangbusters Today

Heat Biologics (HTBX) stock is heating up on Tuesday after revealing interim data from a Phase 2 trial of its lung cancer treatment. The post Heat Biologics News: Why HTBX Stock Is Going Gangbusters Tod...

7 months ago - InvestorPlace

Heat Biologics Cell Therapy Shows Survival Benefit In Mid-Stage Lung Cancer Study, Shares Rally

Heat Biologics Inc (NASDAQ: HTBX) soars in premarket on the heels of encouraging interim data from the Phase 2 trial evaluating HS-110, in combination with Bristol-Myers Squibb's (NYSE: BMY) Opdivo (niv...

7 months ago - Benzinga